

Ref. No: 1595
Date: 06/03/25
Subject: Treatment of inflammatory diseases

REQUEST & RESPONSE

Q1 – How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of October 2024 to the end of December 2024?

Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

S&O Response

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	<5	26	6
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	0	0	0
Ustekinumab (Wezenla)	<5	16	6

STHK legacy response

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	20	103	<5
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	0	0	0
Ustekinumab (Wezenla)	<5	62	<5

Q2 – How many patients were treated with Stelara and its biosimilars (for any disease) in the months October 2024, November 2024, and December 2024?

Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

S&O Response

Drug Name	October 24	November 24	December 24
Ustekinumab (Stelara)	20	18	12
Ustekinumab (Biosimilars)	<5	9	16

STHK legacy response

Drug Name	October 24	November 24	December 24
Ustekinumab (Stelara)	111	21	46
Ustekinumab (Biosimilars)	21	<5	58